Further investigation revealed that CCL19 could inhibit CRC angiogenesis by promoting miR-206 and inhibiting the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway, which might be a new therapeutic option for anti-vascular therapy of CRC [42]. Here, MAPK1 is linked to colorectal carcinoma.